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CeP-9722 plus temozolomide 150 mg/m2 on days 1–5. the 
initial CeP-9722 dose (cohort 1) was 150 mg/day; dose 
escalation followed a modified Fibonnaci sequence.
Results twenty-six patients received CeP-9722 150–
1,000 mg/day combined with temozolomide. Dose-limiting 
toxicities of asthenia and persistent weight loss at 1,000 mg/
day resulted in 750 mg/day being defined as the MtD and 
recommended dose for further study. Overall, 24 (92 %) 
patients had treatment-related adverse events (traes), 
mostly grade 1 or 2, with nausea, vomiting, and diarrhea 
having the strongest relation to CeP-9722. Four patients had 
grade 3 traes (asthenia, myositis, diarrhea, and fatigue). 
Systemic exposure generally increased with dosage, with 
high inter- and intra-patient variability at all doses. Pharma-
codynamic assessment confirmed ParP inhibition although 
no dose response was apparent. One patient with melanoma 
achieved a partial response (1,000 mg/day).
Conclusions CeP-9722 was adequately tolerated with 
temozolomide; the MtD was 750 mg/day. Only limited 
clinical activity was observed.
Keywords ParP inhibitor · Solid tumors · Phase 1 · 
Dose escalation · temozolomide · Maximum tolerated dose
Introduction
Poly(aDP-ribose) polymerases (ParPs) are a family of 
highly conserved enzymes involved in the regulation of 
numerous cellular functions [1, 2]. ParP-1 and ParP-2 
are nuclear enzymes that are activated in response to Dna 
damage [3, 4]. Once ParP-1 is activated, it forms long 
branched chains of poly(aDP-ribose) (Par) on Dna-asso-
ciated proteins [5]. this creates a negatively charged envi-
ronment and allows access for the enzymes responsible for 
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tion at points of Dna strand break results in poly(aDP-
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and allowing access of other repair enzymes. CeP-9722 
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Dna-damaging chemotherapies.
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base excision repair. the auto-aDP ribosylation of ParP-1 
results in its release from Dna. ParP-1 is also involved in 
other Dna repair processes such as pathways of double-
strand break repair [6].
given that many anticancer therapies act by damag-
ing the Dna in tumor cells, investigating the therapeutic 
potential of agents that block ParP-1, and therefore Dna 
repair, has generated much interest [7, 8]. ParP inhibitors 
have been combined in clinical trials with chemothera-
pies such as temozolomide [9] and topotecan [10–12]. 
the therapeutic potential of ParP inhibitors has also been 
studied in patients with tumors that have defects in the 
Dna repair process such as BrCa loss of function muta-
tions. In these patients, the tumor cells have an impaired 
homologous recombination Dna repair process and are 
particularly vulnerable to further reductions in Dna repair 
capacity by monotherapy treatment with ParP inhibitors 
[13, 14].
CeP-9722 is a pro-drug of CeP-8983, a potent inhibitor 
of ParP-1 and ParP-2 with enzyme IC50 values of 20 and 
6 nm, respectively. the CeP-9722 pro-drug was developed 
in order to try to overcome the low oral bioavailability of 
the poorly soluble CeP-8983. In nonclinical studies, CeP-
8983 increased the sensitivity of chemoresistant tumor cells 
to temozolomide, both in vitro and in xenograft models. 
CeP-8983 was also shown to cause only modest increases 
in the myelotoxicity of temozolomide in studies using the 
CFU-gM colony-forming assay with human bone marrow 
cells [15]. this last finding was considered important since 
the potentiation of myelosuppression by other ParP inhib-
itors has been shown to limit the ability to co-administer 
these agents with full-dose chemotherapy [12, 16].
the purpose of this first-in-human study was to evaluate 
the maximum tolerated dose (MtD), safety, pharmacoki-
netics, pharmacodynamics, and efficacy of the oral ParP-
1/-2 inhibitor CeP-9722 in combination with oral temozo-
lomide in patients with advanced solid tumors.
Methods
Study design
this was an open-label, nonrandomized, multicenter, dose-
escalating phase 1 clinical trial. Patients were enrolled at 
1 center in France and 1 center in the United Kingdom 
between May 19, 2009, and June 20, 2011. the primary 
objective was to identify the MtD of CeP-9722 in com-
bination with temozolomide. Secondary objectives were 
to determine the dose range of CeP-9722 that resulted 
in ParP inhibition in peripheral blood mononuclear 
cells (PBMCs), to characterize the pharmacokinetics of 
CeP-8983, and to document any antitumor activity. Dose 
escalation approximated to a modified Fibonacci sequence 
and followed a standard 3 + 3 design.
the study consisted of a screening period to determine 
patient eligibility, a 14-day cycle in which CeP-9722 was 
administered once daily as monotherapy, and subsequent 
28-day cycles in which CeP-9722 and temozolomide were 
administered as combination therapy. In cycle 1, the first 
patient in each dosing cohort received CeP-9722 on days 
1, 3, 4, and 5, while other patients in each cohort received 
CeP-9722 on days 1–5. In cycle 2, patients received CeP-
9722 and temozolomide on days 1–5 (Supplemental Fig.). 
CeP-9722 was escalated from a starting dose of 150 mg/
day up to 1,000 mg/day, and temozolomide was given at 
the dose of 150 mg/m2/day at all dose levels of CeP-9722. 
Both CeP-9722 and temozolomide were administered in 
the fasted state.
Patients were enrolled in cohorts of 3. enrollment in 
the next cohort commenced when the third patient in the 
current cohort had completed day 28 of cycle 2 without a 
dose-limiting toxicity (Dlt). Patients were considered 
evaluable for determination of the MtD provided that they 
had received all doses of study treatment in cycles 1 and 2. 
If a Dlt was observed in cycle 1 or 2 in 1 patient, 3 addi-
tional patients were treated at this dose level. If only 1 Dlt 
was observed in the cohort of 6 patients, the subsequent 
cohort was opened for enrollment; however, if a Dlt was 
observed in ≥2 patients in a cohort of 3 or 6 patients, dose 
escalation was stopped and that dose was defined as being 
above the dose to be recommended for further study.
Dlt was defined as any ≥grade 3 nonhematologic tox-
icity, with the exception of alopecia, vomiting, or nausea 
in the absence of effective antiemetic treatment, or diarrhea 
in the absence of effective antidiarrheal treatment; grade 4 
neutropenia persisting for more than 7 days or grade 3 neu-
tropenia with fever of 38.5 °C (101.3 °F) or higher; grade 4 
thrombocytopenia or grade 3 thrombocytopenia with clini-
cally significant bleeding; Qtc interval >500 ms or Qtc 
variation from baseline >60 ms on ≥2 electrocardiograms 
(eCgs) performed at the same visit; persistence of ≥grade 
2 nonhematologic toxicity at the initiation of cycles 2 or 3; 
or any prolonged ≥grade 2 myelotoxicity that delays initia-
tion of cycle 3 by more than 1 week.
Patients withdrawing from the study for any reason 
other than a Dlt before completing cycle 2 were replaced. 
Patients demonstrating clinical benefit or evidence of tumor 
response and/or no significant toxicity were eligible to 
receive additional cycles of CeP-9722 in combination with 
temozolomide per investigator discretion.
Patient population
Men and women aged ≥18 years with a histologically or 
cytologically confirmed advanced solid tumor considered 
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unresponsive or poorly responsive to accepted therapies 
were eligible for study enrollment. Other key inclusion cri-
teria were adequate renal and hepatic function, and bone 
marrow reserve; an eastern Cooperative Oncology group 
(eCOg) performance status of 0–2; a life expectancy of 
≥12 weeks; evaluable disease by response evaluation Cri-
teria in Solid tumors (reCISt) 1.0 criteria; no prior chem-
otherapy within past 3 weeks, nitrosourea treatment within 
past 6 weeks, or radiotherapy within past 4 weeks; written 
informed consent; and agreement to use appropriate contra-
ceptive measures.
the main exclusion criteria were a primary brain tumor 
requiring a systemic premedication with anticonvul-
sive agents; brain metastases with symptoms in the prior 
4 weeks; marked baseline prolongation of Qt/Qtc inter-
val, risk factors for torsade de pointes, family history of 
long Qt syndrome, heart failure, or use of concomitant 
treatment known to prolong Qt/Qtc interval; previous 
hypersensitivity reactions to any of the components of 
CeP-9722, temozolomide, or dacarbazine; an active gas-
troduodenal ulcer, uncontrolled high blood pressure (sys-
tolic >150 mmHg and diastolic >90 mmHg with medica-
tion), uncontrolled diabetes mellitus, uncontrolled angina 
pectoris, recent myocardial infarction, cerebrovascular 
event within 6 months of study entry, or preexisting coagu-
lopathy; concomitant uncontrolled infection; or severe sys-
temic disease.
the study was conducted in full accordance with the 
good Clinical Practice: Consolidated guidance approved 
by the International Conference on Harmonisation and 
applicable national and local laws and regulations.
Safety and efficacy assessments
Safety was assessed using adverse event data, clinical labo-
ratory test results, vital signs measurement, eCg findings, 
physical examination findings, eCOg performance status, 
and concomitant medication usage.
tumor assessment was performed within 4 weeks before 
the first dose of study drug and within the fourth week of 
cycle 2 using computed tomography or magnetic resonance 
imaging with contrast. In patients who continued treatment, 
tumor assessment was performed every 2 cycles and at the 
end of treatment visit, at the discretion of the investigator.
Pharmacokinetic/pharmacodynamic assessments
Pharmacokinetic serum samples were collected on day 1 
of cycle 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 h 
post-dose; and on day 5 of cycle 1 and cycle 2 pre-dose, 
and 0.5, 1, 2, 3, 4, 6, 8, 10, 24, and 48 h post-dose. Urine 
samples were obtained on day 1 of cycle 1 during 4 inter-
vals in the 24 h following study drug administration. 
Pharmacokinetic parameters (area under the plasma drug 
concentration–time curve from time 0 to infinity [aUC0–∞], 
aUC from time 0 to the time of the last measurable drug 
concentration [aUC0–t], aUC for 1 dosing interval [aUCτ] 
following multiple doses, maximum observed plasma con-
centration [Cmax], and time to maximum observed plasma 
concentration [Tmax]) were summarized at each visit (day 
1 of cycle 1 and day 5 of cycles 1 and 2) using descriptive 
statistics.
Pharmacodynamics were assessed by the measurement 
of Par concentrations in PBMCs. PBMCs were isolated at 
site, and the frozen cell pellet was sent to a central labora-
tory (trevigen Inc., gaithersburg, MD, USa) for process-
ing and analysis by Par enzyme-linked immunosorbent 
assay (elISa) [17]. Pharmacodynamic samples were col-
lected on 2 consecutive days at screening visits and on days 
1, 5 (pre-dose and 2 h [cycle 1 only], 6 h, and 24 h post-
dose), and 8 (at the time of hematology laboratory testing). 
the Par concentrations in the 2 screening samples and the 
day 1 pre-dose sample were averaged to provide a baseline 
value, and the percentage inhibition from baseline was cal-
culated in the post-dose samples.
Results
Patient disposition and demographics
In total, 33 patients with solid tumors were screened for 
study eligibility; of these, 26 patients met the entry criteria 
and were enrolled. the mean age of the patients was 52.8 
(range 18–71) years. all of the patients had had previous 
chemotherapy; 23 patients (88 %), surgery; 13 patients 
(50 %), radiotherapy; and 10 patients (38 %), target therapy 
(table 1).
Maximum tolerated dose
three patients were enrolled at the starting dose of 150 mg/
day and completed the treatment in the first 2 cycles with-
out Dlt. One patient in the second cohort (300 mg/day) 
had a Dlt of grade 3 fatigue, and the cohort was expanded 
to six patients. no other Dlts were observed in the sec-
ond or third cohort (500 mg/day, 3 patients). One patient 
in the fourth cohort (750 mg/day) had a grade 3 myositis 
on day 15 of cycle 1, and the cohort was expanded to six 
patients. no other Dlts were observed, and three patients 
were enrolled in the fifth cohort (1,000 mg/day). two of 
these patients developed Dlts (grade 3 asthenia on day 5 
of cycle 1; persistent grade 2 weight loss in cycle 2). It was 
therefore concluded that, at a dose of 1,000 mg/day, the tol-
erable dose had been exceeded, and 3 additional patients 
were enrolled at a dose of 750 mg/day without Dlt.
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In total, 8 patients (31 %) withdrew from the study 
before completion of day 28 of cycle 2. the recommended 
phase 2 dose for CeP-9722 was established at a dose of 
750 mg/day, days 1–5, in combination with temozolomide 
at a dose of 150 mg/m2/day, days 1–5, in a 28-day cycle.
Safety
all patients enrolled in the study had 1 or more adverse 
events during the treatment period. the most commonly 
occurring adverse events (≥20 % of patients) were nau-
sea (77 %), vomiting (65 %), constipation (50 %), head-
ache (50 %), diarrhea (42 %), asthenia (42 %), abdominal 
pain (35 %), anorexia (35 %), fatigue (31 %), and anemia 
(23 %).
the most common severe adverse events were abdom-
inal pain (1 patient at 300 mg/day, 2 patients at 750 mg/
day), asthenia (1 patient each at 300 and 1,000 mg/day), 
and noncardiac chest pain (2 patients at 750 mg/day). Six 
patients had grade 3–4 laboratory hematologic toxicities 
(5 lymphopenia [3 at 750 mg/day and 1 each at 300 and 
1,000 mg/day] and 1 anemia at 750 mg/day).
Dose delays due to hematological toxicity occurred in 
three patients (all at a CeP-9722 dose of 750 mg/day). 
Four patients withdrew due to adverse events: 2 due to 
asthenia (750 and 1,000 mg/day; both possibly/probably 
related to treatment), 1 due to weight loss (1,000 mg/
day, possibly related), and 1 due to respiratory distress 
(150 mg/day, not considered related). the patient with res-
piratory distress died. there were four additional deaths, 
all due to disease progression, which were not considered 
treatment related.
treatment-related adverse events during cycle 1 (mono-
therapy) and subsequent cycles (combination therapy) are 
presented in table 2. events of headache, diarrhea, nau-
sea, and vomiting showed the clearest relationship to dose 
during monotherapy. Similar trends were observed dur-
ing combination therapy (cycles 2 and beyond). grade 3 
traes occurred in two patients during monotherapy with 
CeP-9722 (asthenia and myositis), and in two patients dur-
ing combination therapy (diarrhea and fatigue).
Central review of eCgs showed no clinically significant 
abnormalities.
efficacy
In total, 22 of the 26 patients enrolled in the study 
were evaluated for efficacy (table 3). One patient 
Table 1  Patient demographics and disease characteristics
ECOG eastern Cooperative Oncology group, SD standard deviation
a
 Other includes 1 each: abdominal/pelvic sarcoma, adenocarcinoma of the jejunum, atypical carcinoid cancer, cervix uteri cancer, cholangio-
carcinoma, external ear cancer, gallbladder cancer, esophageal cancer, lung cancer, melanoma, prostate cancer, stomach cancer, and urothelial 
carcinoma












age in years, mean ± SD 55.3 ± 11.72 53.7 ± 12.91 52.3 ± 7.23 50.6 ± 15.10 57.0 ± 7.94 52.8 ± 12.24
gender
 Female 3 (100) 4 (67) 2 (67) 7 (64) 2 (67) 18 (69)
 Male 0 2 (33) 1 (33) 4 (36) 1 (33) 8 (31)
Smoking status/medications affecting gastric pH
 Smoker 0 4 (67) 0 2 (18) 1 (33) 7 (27)
















 Colorectal 0 0 1 (33) 1 (9) 0 2 (8)
 Othera 1 (33) 4 (67) 2 (67) 4 (36) 2 (67) 13 (50)
eCOg status
 0 2 (67) 2 (33) 2 (67) 4 (36) 1 (33) 11 (42)
 1 1 (33) 4 (67) 1 (33) 7 (64) 1 (33) 14 (54)
 2 0 0 0 0 1 (33) 1 (4)
Prior anticancer radiotherapy 3 (100) 2 (33) 1 (33) 7 (64) 0 13 (50)
Prior systemic anticancer chemotherapy 3 (100) 6 (100) 3 (100) 11 (100) 3 (100) 26 (100)
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demonstrated a confirmed partial response according 
to reCISt criteria, four patients had stable disease, 
and 17 patients had progressive disease. the patient 
demonstrating a partial response (a 58 % reduction 
in target lesions, as defined by reCISt criteria) was 
a 66-year-old man with melanoma previously treated 
with paclitaxel and pazopanib who received CeP-9722 
1,000 mg/day. the partial response was first observed 
after 6 cycles of treatment and lasted 5.8 months. the 
patient did not experience disease progression during 
the study; however, CeP-9722 and temozolomide were 
stopped after cycle 12 due to concerns over temozolo-
mide cumulative toxicity.
Pharmacokinetics
Conversion of CeP-9722 into its active form is rapid; 
thus, systemic exposure was assessed by measuring the 
plasma concentration of CeP-8983. In general, systemic 
exposure increased with dose, but there was a high degree 
Table 2  all grades of 
treatment-related adverse events 
in at least two patients who 
received CeP-9722 alone or 
combined with temolozomide












Cycle 1: single-agent CeP-9722
 nausea 0 1 (17) 1 (33) 8 (73) 2 (67) 12 (46)
 Diarrhea 0 0 0 5 (45) 2 (67) 7 (27)
 Vomiting 0 1 (17) 0 4 (36) 2 (67) 7 (27)
 abdominal pain 0 0 0 2 (18) 0 2 (8)
 Constipation 0 0 0 2 (18) 0 2 (8)
 asthenia 0 1 (17) 0 3 (27) 1 (33) 5 (19)
 Fatigue 1 (33) 1 (17) 0 2 (18) 0 4 (15)
 Blood creatinine phosphokinase increased 0 0 0 1 (9) 1 (33) 2 (8)
 anorexia 0 0 0 1 (9) 2 (67) 3 (12)
 Headache 0 1 (17) 2 (67) 5 (45) 2 (67) 10 (38)
Cycles ≥ 2: CeP-9722 combined with temozolomide
 leukopenia 1 (33) 0 0 2 (18) 0 3 (12)
 anemia 0 0 1 (33) 1 (9) 0 2 (8)
 neutropenia 1 (33) 0 0 1 (9) 0 2 (8)
 thrombocytopenia 1 (33) 0 0 1 (9) 0 2 (8)
 nausea 1 (33) 3 (50) 1 (33) 8 (73) 2 (67) 15 (58)
 Vomiting 1 (33) 1 (17) 1 (33) 8 (73) 2 (67) 13 (50)
 Diarrhea 0 0 0 3 (27) 2 (67) 5 (19)
 Constipation 0 0 0 2 (18) 1 (33) 3 (12)
 Dyspepsia 0 0 0 2 (18) 0 2 (8)
 asthenia 0 0 2 (67) 4 (36) 0 6 (23)
 Fatigue 0 1 (17) 0 4 (36) 1 6 (23)
 gamma-glutamyltransferase increased 0 0 1 (33) 2 (18) 0 3 (12)
 Hemoglobin decreased 0 1 (17) 0 2 (18) 0 3 (12)
 Weight decreased 0 1 (17) 0 1 (9) 1 (33) 3 (12)
 aspartate aminotransferase increased 0 0 1 (33) 1 (9) 0 2 (8)
 anorexia 0 1 (17) 0 1 (9) 2 (67) 4 (15)
 Headache 0 2 (33) 2 (67) 5 (45) 2 (67) 11 (42)
Table 3  Best tumor response according to reCISt 1.0 criteria












1 150 2 0 0 2
2 300 6 0 1 5
3 500 3 0 2 1
4 750 9 0 1 8
5 1,000 2 1 0 1
total 22 1 4 17
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of inter- and intra-patient variability (Fig. 1). Smoking 
and the concomitant use of agents that raise gastric pH 
were associated with low plasma exposure (table 4). In 
addition, a general trend toward higher exposure on day 1 
of cycle 1 than that on day 5 of cycle 1 and day 5 of cycle 
2 was observed, which may be related to changes in drug 
absorption or metabolism. Mean aUC0–t of CeP-8983 for 
nonsmokers not receiving gastric pH-modifying medica-
tions versus those in smokers and/or patients receiving 
gastric pH-modifying medications were, respectively, 
4,960.6 ng h/ml versus 2,747.3 ng h/ml for day 1 of 
cycle 1; 3,138.0 ng h/ml versus 1,339.3 ng h/ml for day 
5 of cycle 1; and 2,574.4 ng h/ml versus 1,457.9 ng h/ml 
for day 5 of cycle 2. 
Pharmacodynamics
a Par biomarker assay was performed to determine the 
degree of ParP inhibition in PBMCs as the dose of CeP-
9722 was escalated in the study. the laboratory elISa 
measures Par in an extract from a processed cell pel-
let of PBMCs. as applied to the clinical setting, the assay 
was found to be sensitive to variations in sample handling 
and processing, which introduced considerable variabil-
ity. However, a reduction in Par concentrations relative 
to baseline was observed at the 2 and 6 h post-dose time 
points in cycle 1 when CeP-9722 was given without temo-
zolomide. the reduction in Par concentrations at the 6 h 
post-dose time point in cycle 2 was less marked (Fig. 2). 
Fig. 1  Mean (SD) area under 
the plasma drug concentration–
time curve from time 0 to the 
time of the last measurable drug 
concentration (aUC0–t) of CeP-
8983 after CeP-9722 adminis-
tration on days 1 and 5 of cycle 
1 (C1D1, C1D5) and on day 5 
of cycle 2 (C2D5)
Table 4  Pharmacokinetic parameters for CeP-8983 by smoking status/receiving medications that affect gastric pH (day 5 of cycle 1)
AUC0–∞ area under the plasma drug concentration–time curve from time 0 to infinity, AUC0–t area under the plasma drug concentration–time 
curve from time 0 to the time of the last measurable drug concentration, AUCτ area under the plasma drug concentration–time curve for 1 
dosing interval, CL/F total body clearance from plasma after oral administration, Cmax maximum observed plasma concentration, λz terminal 
plasma elimination rate-constant,t1/2 half-life, tmax time to maximum observed plasma concentration, V/F apparent volume of distribution after 
oral administration
Pharmacokinetic parameters,  
mean ± SD
nonsmoker without medication  
affecting gastric pH n = 13
Smoker and/or with medication 
affecting gastric pH n = 11
Cmax (ng/ml) 607.5 ± 319.87 352.5 ± 380.57
aUC0–∞ (ng h/ml) 4,111.0 ± 4,126.79 2,838.9 ± 5,740.57
aUC0–t (ng h/ml) 3,138.0 ± 2,160.74 1,339.3 ± 2,127.07
aUCτ (ng h/ml) 3,851.1 ± 3,578.78 2,304.7 ± 4,161.29
tmax (h) 0.6 ± 0.66 0.6 ± 0.66
t1/2 (h) 1.0 ± 0.59 0.7 ± 0.77
Cl/F (l/h) 20.4 ± 25.80 67.1 ± 62.14
V/F(l) 58.1 ± 60.23 102.3 ± 100.76
Percentage extrapolation (%) 3.7 ± 3.82 5.5 ± 8.29
λz (1/h) 0.1 ± 0.13 0.2 ± 0.21
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there was no apparent relationship between dose of CeP-
9722 and the degree of inhibition of ParP as measured by 
the Par elISa.
Discussion
the exquisite sensitivity of tumor cells deficient in BrCa 
function to ParP inhibitors in vitro has generated much 
hope that this activity could be translated to clinical practice 
[18, 19]. Indeed, early clinical trials of monotherapy with 
the ParP inhibitor olaparib realized much of this promise 
with reCISt responses in 30–40 % of breast and ovarian 
cancer patients with BrCa mutations [14, 20]. although 
a randomized phase 2 study of olaparib versus liposomal 
doxorubicin failed to show a benefit in progression-free 
survival in BrCa-mutated ovarian cancer patients [21], 
a randomized study of olaparib versus placebo as mainte-
nance therapy following response to a platinum-based regi-
men did show such a benefit in patients with ovarian cancer 
[22]. this benefit in progression-free survival was statisti-
cally significant for both patients with and without BrCa 
mutations, indicating the broader potential for ParP inhib-
itors, and active clinical development for this indication is 
ongoing for many of the agents in the class [11].
the benefit of using a ParP inhibitor in combina-
tion with chemotherapy is less well established. an early 
study of rucaparib showed that this ParP inhibitor could 
be successfully combined with temozolomide [9]. In a 
subsequent phase 2 study of this combination in patients 
with metastatic melanoma, the progression-free survival 
was longer than that expected from historical controls; 
however, approximately half of the patients required a 
reduction in the dose of temozolomide due to enhanced 
myelosuppression [23]. Potentiation of the myelosuppres-
sive effects of chemotherapy has been observed with other 
ParP inhibitors, including olaparib and veliparib, and this 
has limited the doses of chemotherapies that can be used in 
these combinations [24]. It was for this reason that CeP-
9722 was of particular interest since nonclinical studies had 
shown that, at concentrations relevant to clinical use, CeP-
8983 (the active form of CeP-9722) had only minor effects 
on the myelotoxicity of temozolomide [15].
In the current study, CeP-9722 was successfully com-
bined with temozolomide at a dose of 150 mg/m2. Dose 
delays due to hematological toxicity were infrequent. grade 
3/4 neutropenia was not observed at any of the scheduled 
study visits. the MtD of CeP-9722 was eventually defined 
by asthenia and weight loss rather than hematological 
toxicity. although this lack of potentiation of myelosup-
pression was encouraging, the degree of ParP inhibition 
achieved remains unclear. the Par elISa assay selected 
for the study had proven reliable in a laboratory setting, but 
was very sensitive to variations in sample handling and pro-
cessing in the clinic. a clear reduction in PBMC Par con-
centrations could be observed in samples taken 2 and 6 h 
post-dose, relative to a pre-dose baseline value; however, 
there was considerable variability and no apparent relation-
ship to dose. the inhibitory effects on Par production also 
were lost by the 24 h post-dose sample suggesting that a 
twice-daily dose might be a better treatment schedule.
the pharmacokinetics of CeP-8983 also showed a high 
degree of inter- and intra-patient variability. notably, con-
centrations of CeP-8983 were lower in patients who were 
taking proton pump inhibitors and other medications that 
would raise gastric pH. this is likely to be a result of 
poorer absorption of CeP-8983, which is poorly soluble 
in nonacidic environments. Patients who smoked also had 
Fig. 2  Inhibition of poly(aDP-
ribose) polymerase (ParP) as 
measured by poly(aDP-ribose) 
(Par) concentrations in periph-
eral blood mononuclear cells 
(PBMCs). the figure shows the 
Par concentrations in PBMCs 
at study time points (C cycle, 
D day, HR hour, PD post-dose) 
expressed as a mean (Se) 
percentage inhibition from the 
pre-study baseline concentration
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lower CeP-8983 plasma exposure, most probably due to 
increased metabolism by the smoking-induced increase in 
cytochrome CYP1a2.
Clinical activity in the form of reCISt response was 
limited to 1 patient in this study; a durable partial response 
was recorded in 1 patient treated at the highest dose of 
CeP-9722 (1,000 mg/day). Four additional patients (300–
750 mg/day) had stable disease as best response. In view of 
the lack of potentiation of myelotoxicity of temozolomide, 
and the generally good tolerability observed, further clini-
cal study of CeP-9722 would be warranted if the low and 
variable absorption of the drug could be overcome by an 
improved formulation. twice-daily administration should 
also be considered.
Conclusion
Data from previous preclinical and clinical studies have 
shown that ParP inhibitors potentiate the cytotoxicity of 
Dna-damaging chemotherapy and ionizing radiation [8]. 
the current study confirmed ParP inhibition by CeP-
9722. CeP-9722 at a dose of 750 mg/day was the high-
est dose that was adequately tolerated in combination 
with temozolomide at a dose of 150 mg/m2. Dlts were 
nonhematological in nature. Pharmacokinetic and phar-
macodynamic results indicate that further formulation 
development and a twice-daily dosing schedule should be 
considered.
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